Food and Drug Law Journal | Volume 76 | Number 4

Food and Drug Law Journal | Volume 76 | Number 4

Misleading and Deceptive? A Look into Educational and Promotional Messages Comparing the Nature of Biologics and Biosimilars  Francisco Lemos Ribeiro Filho ABSTRACT This Article assesses the legal issues arising from claims that companies commercializing original biological medicines (biologics) have disseminated messages to mislead the public into believing biosimilars are less safe and effective than [...]

Agencies Unbound: How COVID-19 Prompted Regulatory Flexibility and What it May Mean for the Future Brian D. Eyink, Elizabeth Barr Fawell, Steven Steinborn & Anneke Baran Altieri ABSTRACT The COVID-19 crisis called for governmental responses of unprecedented scale, scope, and speed. COVID-19 stressed not only medical infrastructure, supply chains, and financial systems, but also [...]

Is PPPA DOA For CBD? James O’Reilly ABSTRACT Wide access to and extensive marketing of flavored forms of cannabidiol (CBD) is likely to lead to many child ingestion incidents, exceeding the current dozens of published medical reports about harms to children. Refusal by the federal agency responsible for child protective packaging use with drug [...]

Food and Drug Law Journal | Volume 76 | Number 3

Food and Drug Law Journal | Volume 76 | Number 3

Food and Drug Law Journal | Volume 76 | Number 3

Food and Drug Law Journal | Volume 76 | Number 3

Food and Drug Law Journal | Volume 76 | Number 2